Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) today announces the result of Medivir's voluntary redemption programme. The redemption programme comprised a total of 6,738,655 shares in Medivir. Upon completion of the application period, a total of 6,647,060 shares have been registered for redemption, whereof 131,589 series A shares and 6,515,471 series B shares, corresponding to an acceptance level of 98.6 per cent. In total, cash proceeds of approximately SEK 857.5 million will be distributed to the shareholders, corresponding to SEK 129 per redeemed share, to be paid around 24 March 2017. Following completion of the redemption programme, the total number of outstanding shares in Medivir will amount to 20,318,977 shares, whereof 474,769 series A shares and 19,844,208 series B shares, and the total number of votes will amount to 24,591,898 votes. Commission-free sale For the commission-free sale of redemption rights, the average sales proceeds amounted to SEK 13.26 per redemption right.